文献速递脑血管病外科神经重症

新型支架双支架辅助栓塞治疗急性蛛网膜下腔出血动脉瘤

Dual Stenting with New-Generation Stents for Aneurysm Embolization in Acute Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2021-07-03

该回顾性研究评估了16例急性蛛网膜下腔出血患者使用双交叉支架(X/Y型)辅助栓塞的临床与影像结果。技术成功率100%,但25%手术出现并发症,3例(18.8%)发生不良事件(2例支架血栓、1例动脉瘤破裂)。作者认为在特定患者可接受手术风险的前提下,新型低剖面支架可用于急性期双支架辅助栓塞。

要点

  • 双交叉支架辅助栓塞在急性蛛网膜下腔出血中技术成功率高,但并发症风险需重视。
  • 新型低剖面开环支架组合可能是急性期双支架辅助栓塞的可行选择。
  • 手术相关永久病残率6.3%,总体永久病残率12.5%,无手术相关死亡。

核心结论

  • 新型低剖面支架行双交叉支架辅助栓塞可用于急性蛛网膜下腔出血,但需权衡明确的手术风险。
  • 新型开环支架组合似乎是急性蛛网膜下腔出血双交叉支架辅助栓塞的可行选择。

研究设计与样本

  • 回顾性评估16例急性蛛网膜下腔出血接受双交叉支架辅助栓塞的患者(10例女性,平均年龄55.8岁)。
  • 手术在出血后3.2±2.6天(范围1-10天)内完成,仅使用最新一代颅内支架。

主要发现

  • 技术成功率为100%。
  • 25%的手术出现并发症,3例(18.8%)发生不良事件:2例支架血栓、1例动脉瘤破裂。
  • 手术相关病残率和死亡率分别为6.3%和0,总体永久病残率和死亡率分别为6.3%和12.5%。
  • 平均临床随访160±156天(范围1-540天)内未记录到额外神经事件。

临床怎么用

  • 在特定急性蛛网膜下腔出血患者中,若可接受明确的手术风险,可考虑使用新型低剖面支架行双交叉支架辅助栓塞。

局限性

  • 回顾性设计,样本量小(16例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endosaccular treatment is the backbone of endovascular treatment for acutely ruptured aneurysms. Stent-assisted coiling is a niche technique in this context. Data on X-stenting or Y-stenting (dual crossing stenting, DCS) in the acute phase after subarachnoid hemorrhage (aSAH) are scarce, and the impact of stent properties on the outcome is unknown. We retrospectively evaluated the clinical and imaging results of DCS in patients treated for aSAH. METHODS: Patients with aSAH treated with DCS were evaluated retrospectively. Patient and procedural characteristics were evaluated to determine clinical outcomes, associated complications, and follow-up imaging findings. RESULTS: Sixteen procedures (16 patients; 10 women, mean age 55.8) were performed within 3.2 ± 2.6 days (range 1-10 days) of aSAH. Only the latest generation of intracranial stents (dual Neuroform Atlas-12 cases, dual Leo Baby-2 cases, Neuroform Atlas with Acclino Flex, or Leo Baby-2 cases) were used. Technical success rate was 100%; however, 25% of the procedures were complicated, leading to adverse events in 3 procedures (18.8%; 2 stent thrombosis, 1aneurysm rupture). Procedure-related morbidity and mortality and overall permanent morbidity and mortality were 6.3%, none, 6.3%, and 12.5%, respectively. No additional neurologic events were noted on a mean clinical follow-up of 160 ± 156 (range: 1-540) days. CONCLUSIONS: Our findings and the patient-by-patient data we extracted from the literature suggest that DCS can be performed with new-generation, low-profile stents in aSAH if a definite procedural risk is acceptable for a specific patient. New-generation open-cell stent combinations appear as a viable choice for DCS in aSAH.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Sayin B, Karaman A, Balci S, et al. Dual Stenting with New-Generation Stents for Aneurysm Embolization in Acute Subarachnoid Hemorrhage. World Neurosurg. 2021. PMID: 34229098. doi:10.1016/j.wneu.2021.06.135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。